검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ritonavir |
Overview Company | AbbVie (prior sponsor, Abbott) |
Overview Modality | ADC |
Overview Target | Neoplasm Metastasis |
Overview Indication | HIV Infections |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted and B-cell maturation (BCMA)-targeted chimeric antigen receptor |
MoA Biomarker | biomarker activity in CS biopsy samples at day 30 |
PK/PD Half-life | 6.84 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.. Drug repurposing presents as a promising strategy in oncology, particularly for urological prostate and bladder cancers, where resistance to current therapy remains a challenge. This study evaluated the anticancer potential of three antiretroviral d… |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 8% |
Clinical Result source | ClinicalTrials.gov NCT03383692 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ritonavir |
Overview Company | AbbVie (prior sponsor, Abbott) |
Overview Modality | ADC |
Overview Target | Neoplasm Metastasis |
Overview Indication | HIV Infections |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted and B-cell maturation (BCMA)-targeted chimeric antigen receptor |
MoA Biomarker | biomarker activity in CS biopsy samples at day 30 |
PK/PD Half-life | 6.84 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.. Drug repurposing presents as a promising strategy in oncology, particularly for urological prostate and bladder cancers, where resistance to current therapy remains a challenge. This study evaluated the anticancer potential of three antiretroviral d… |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 8% |
Clinical Result source | ClinicalTrials.gov NCT03383692 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교